Row:(MILLIONS OF DOLLARS AND SHARES, EXCEPT PER SHARE DATA) 	2018 	2017 	2016
Row:Revenue $ 	5,825 $ 	5,307 $ 	4,888
Row:Costs and expenses:
			Row:Cost of sales(a) 	1,911 	1,775 	1,666
Row:Selling, general and administrative expenses(a) 	1,484 	1,334 	1,364
Row:Research and development expenses(a) 	432 	382 	376
Row:Amortization of intangible assets 	117 	91 	85
Row:Restructuring charges and certain acquisition-related costs 	68 	19 	5
Row:Interest expense, net of capitalized interest 	206 	175 	166
Row:Other (income)/deductions––net 	(83) 	6 	(2)
Row:Income before provision for taxes on income 	1,690 	1,525 	1,228
Row:Provision for taxes on income 	266 	663 	409
Row:Net income before allocation to noncontrolling interests 	1,424 	862 	819
Row:Less: Net loss attributable to noncontrolling interests 	(4) 	(2) 	(2)
Row:Net income attributable to Zoetis $ 	1,428 $ 	864 $ 	821
Row:Earnings per share attributable to Zoetis Inc. stockholders:
			Row:Basic $ 	2.96 $ 	1.76 $ 	1.66
Row:Diluted $ 	2.93 $ 	1.75 $ 	1.65
Row:Weighted-average common shares outstanding:
			Row:Basic 	483.063 	489.918 	495.715
Row:Diluted 	486.898 	493.161 	498.225
Row:Dividends declared per common share $ 	0.542 $ 	0.441 $ 	0.390
Row:(a) 			Row:(MILLIONS OF DOLLARS, EXCEPT PER SHARE DATA) 	December 31, 2018 	December 31,
2017
Row:Assets
		Row:Cash and cash equivalents(a) $ 	1,602 $ 	1,564
Row:Short-term investments 	99 	—
Row:Accounts receivable, less allowance for doubtful accounts of $24 in 2018 and $25 in 2017 	1,036 	998
Row:Inventories 	1,391 	1,427
Row:Other current assets 	271 	228
Row:Total current assets Property, plant and equipment, less accumulated depreciation of $1,599 in 2018 and $1,471 in 2017 	4,399 1,658 	4,217
1,435
Row:Goodwill Identifiable intangible assets, less accumulated amortization 	2,519 2,046 	1,510
1,269
Row:Noncurrent deferred tax assets Other noncurrent assets 	61 94 	80
75
Row:Total assets $ 	10,777 $ 	8,586
Row:Liabilities and Equity
		Row:Short-term borrowings $ 	9 $ 	—
Row:Accounts payable 	313 	261
Row:Dividends payable 	79 	61
Row:Accrued expenses 	487 	432
Row:Accrued compensation and related items 	266 	236
Row:Income taxes payable Other current liabilities 	35 34 	60
44
Row:Total current liabilities 	1,223 	1,094
Row:Long-term debt, net of discount and issuance costs Noncurrent deferred tax liabilities 	6,443 474 	4,953
380
Row:Other taxes payable Other noncurrent liabilities 	265 187 	172
201
Row:Total liabilities 	8,592 	6,800
Row:Commitments and contingencies (Note 17)
Stockholders' equity:
		Row:Preferred stock, $0.01 par value; 1,000,000,000 authorized, none issued 	— 	—
Row:Common stock, $0.01 par value: 6,000,000,000 authorized, 501,891,243 and 501,891,243 shares issued;
479,562,326 and 486,130,461 shares outstanding at December 31, 2018 and 2017, respectively 	5 	5
Row:Treasury stock, at cost, 22,328,917 and 15,760,782 shares of common stock at December 31, 2018 and 2017,
respectively 	(1,487) 	(852)
Row:Additional paid-in capital 	1,026 	1,013
Row:Retained earnings Accumulated other comprehensive loss 	3,270 (629) 	2,109
(505)
Row:Total Zoetis Inc. equity Equity attributable to noncontrolling interests 	2,185 — 	1,770
16
Row:Total equity 	2,185 	1,786
Row:Total liabilities and equity $ 	10,777 $ 	8,586
Row:(MILLIONS OF DOLLARS) 	Year Ended December 31,
2018 2017 2016
Row:Operating Activities
Net income before allocation to noncontrolling interests $ Adjustments to reconcile net income before noncontrolling interests to net cash
provided by operating activities:
Depreciation and amortization expense 	1,424 $ 862 $ 819
308 242 240
Row:Share-based compensation expense 	53 44 37
Row:Asset write-offs and asset impairments 	4 3 5
Row:Net (gain)/loss on sales of assets 	(42) 11 (26)
Row:Provision for losses on inventory 	54 54 105
Row:Deferred taxes(a) 	(112) 127 (55)
Row:Employee benefit plan contribution from Pfizer Inc. 	3 3 3
Row:Other non-cash adjustments 	(14) 10 19
Row:Other changes in assets and liabilities, net of acquisitions and divestitures
	Row:Accounts receivable Inventories 	(67) (50) 15
61 19 (101)
Row:Other assets 	(42) (16) (50)
Row:Accounts payable 	37 (10) (28)
Row:Other liabilities 	56 (38) (290)
Row:Other tax accounts, net 	67 85 20
Row:Net cash provided by operating activities 	1,790 1,346 713
Row:Investing Activities
	Row:Capital expenditures 	(338) (224) (216)
Row:Acquisition of Abaxis, net of cash acquired 	(1,884) — —
Row:Other acquisitions 	(114) (82) (88)
Row:Net proceeds from sales of assets 	56 37 90
Row:Proceeds from maturities and redemptions of investments 	28 — —
Row:Other investing activities 	(7) (1) —
Row:Net cash used in investing activities 	(2,259) (270) (214)
Row:Financing Activities
Increase/(decrease) in short-term borrowings, net 	8 — (5)
Row:Principal payments on long-term debt 	— (750) (400)
Row:Proceeds from issuance of long-term debt—senior notes, net of discount and fees Payment of contingent consideration related to previously acquired assets 	1,485 1,231 —
(12) (7) (32)
Row:Share-based compensation-related proceeds, net of taxes paid on withholding shares and excess tax benefits 	19 24 25
Row:Purchases of treasury stock 	(698) (500) (300)
Row:Cash dividends paid 	(243) (206) (188)
Row:Acquisition of a noncontrolling interest 	(26) (43) —
Row:Payment of debt issuance costs 	— — (3)
Row:Net cash provided by/(used in) financing activities 	533 (251) (903)
Row:Effect of exchange-rate changes on cash and cash equivalents 	(26) 12 (23)
Row:Net increase/(decrease) in cash and cash equivalents 	38 837 (427)
Row:Cash and cash equivalents at beginning of period 	1,564 727 1,154
Row:Cash and cash equivalents at end of period $ 	1,602 $ 1,564 $ 727
Row:See Notes to Consolidated Financial Statements, which are an integral part of these 	statements.
